A secondary objective of this head-to-head study of lisdexamfetamine dimesylate (LDX) and atomoxetine (ATX) was to assess treatment response rates in children and adolescents with attention-deficit hyperactivity disorder (ADHD) and an inadequate response to methylphenidate (MPH). The primary efficacy and safety outcomes of the study, SPD489-317 (ClinicalTrials.gov NCT01106430), have been published previously.
Dittmann, R. W., Cardo, E., Nagy, P., Anderson, C. S., Adeyi, B., Caballero, B., Hodgkins, P., Civil, R., & Coghill, D. R. (2014). Treatment response and remission in a double-blind, randomized, head-to-head study of lisdexamfetamine dimesylate and atomoxetine in children and adolescents with attention-deficit hyperactivity disorder. CNS Drugs, 28(11), 1059-1069. https://doi.org/10.1007/s40263-014-0188-9